EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unraveling the role of MCM7 in cancer: a comprehensive analysis and functional validation from pan-cancer to lung adenocarcinoma

Xiaozhou Xie, Jie Li, Yuchen Jia, Yuxi Zhang, Jiongdi Lu, Feng Cao, Fei Li

Frontiers in Oncology · 02.11.2026 · 16

DOI: 10.3389/fonc.2026.1949632 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 02.11.2026. Verfasst von Xiaozhou Xie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Minichromosome maintenance protein 7 (MCM7), an integral component of the DNA replication licensing complex, has been implicated in diverse human malignancies. However, a holistic, multi-omics evaluation of its oncogenic repertoire across a broad spectrum of cancers remains conspicuously absent. We comprehensively characterized the expression landscape, prognostic significance, genetic aberrations, and immunomodulatory correlations of MCM7 across 33 cancer types, and further experimentally corroborated its functional and mechanistic roles in lung adenocarcinoma (LUAD).

Methods

We leveraged multi-omics datasets from TCGA, GTEx, CPTAC, and HPA to assess MCM7 expression, survival outcomes, and genomic alterations. Correlative analyses were performed with tumor mutational burden, microsatellite instability, cancer-associated fibroblast infiltration, immune checkpoints, and RNA modification regulators. Functionally, MCM7 was silenced via siRNA in LUAD cell lines, followed by comprehensive assessments of proliferation, cell cycle, migration, invasion, and epithelial-mesenchymal transition. Mechanistic exploration was conducted via RNA-sequencing and western blotting.

Results

MCM7 is markedly upregulated in most malignant tumors, and its elevated expression is closely associated with poor survival prognosis. Copy number amplification was identified as the predominant genetic alteration, while the R72C/H mutation was specifically linked to dismal outcomes in glioblastoma. Notably, MCM7 expression displayed robust positive correlations with TMB, MSI, the immune checkpoint HMGB1, and the m 5 C reader ALYREF in most cancer types. Functional enrichment reaffirmed its canonical involvement in cell cycle and DNA replication. In vitro , MCM7 knockdown drastically abrogated LUAD cell viability, colony formation, and metastatic capacity, while inducing G0/G1 phase arrest and reversing EMT phenotypes. Mechanistically, transcriptomic and experimental validations convergently revealed that MCM7 silencing exerts its anti-tumor effects via suppression of the JAK-STAT3 signaling cascade.

Conclusion

Our findings establish MCM7 as a bona fide pan cancer oncogenic determinant and a promising diagnostic/prognostic biomarker. Furthermore, we unveil a novel mechanistic axis linking MCM7 to JAK STAT3 driven inflammatory signaling in LUAD, offering a pre-clinical hypothesis for targeting MCM7 in combination with immunotherapeutic or JAK/STAT inhibitory regimens, although in-vivo validation and toxicity assessment remain essential.

Schlagwörter

Stichwörter der Autor:innen

MCM7human cancerimmune infiltrationlung adenocarcinomasurvival prognosis

Autor:innen und Institutionen

  • Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Clinical Center for Acute Pancreatitis, Capital Medical University, Beijing, China.
  • Department of General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.

Zitieren

APA

Xie, X., Li, J., Jia, Y., Zhang, Y., Lu, J., Cao, F., & Li, F. (2026). Unraveling the role of MCM7 in cancer: a comprehensive analysis and functional validation from pan-cancer to lung adenocarcinoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1949632

Vancouver

Xie X, Li J, Jia Y, Zhang Y, Lu J, Cao F, et al. Unraveling the role of MCM7 in cancer: a comprehensive analysis and functional validation from pan-cancer to lung adenocarcinoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1949632

BibTeX
@article{Xie2026,
  author = {Xie, Xiaozhou and Li, Jie and Jia, Yuchen and Zhang, Yuxi and Lu, Jiongdi and Cao, Feng and Li, Fei},
  title = {Unraveling the role of MCM7 in cancer: a comprehensive analysis and functional validation from pan-cancer to lung adenocarcinoma},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1949632}
}
Kostenlos starten →